AVAX Technologies, Inc. (AVXT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Philadelphia, PA, United States. The current CEO is Adele Sommerfeld.
AVXT has IPO date of 1997-05-15, 9 full-time employees, listed on the Other OTC, a market capitalization of $6.89K.
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
